微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 63.24% | -1.65% | 2.61% | 41/158 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 61.63% | -4.87% | -1.14% | 49/158 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 62.34% | -3.56% | -0.69% | 46/158 | 22.73% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 62.78% | -1.11% | -2.37% | 45/158 | 33.18% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 64.3% | 4.38% | -0.75% | 40/158 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 64.79% | -4.32% | 0.22% | 41/158 | 51.38% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 64.65% | -5.39% | 1.84% | 40/158 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 63.48% | -7.92% | 3.05% | 48/158 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 61.6% | -7.34% | -9.03% | 50/158 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 67.71% | -6.46% | -0.9% | 44/158 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 68.33% | -6.77% | -0.88% | 42/158 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 68.94% | -4.47% | 3.7% | 43/158 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 66.48% | -7.85% | -8.16% | 43/158 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 72.39% | -0.44% | -1.24% | 37/158 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 73.29% | 2% | 1.57% | 31/158 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 72.16% | 0.75% | 0.03% | 34/158 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 72.14% | 2% | -0.78% | 28/158 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 72.7% | 3.22% | 1.51% | 34/158 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 71.62% | 2% | 1.69% | 28/158 | 54.11% | 泽璟制药 | 99.96% | 行业排名> |
| 2019-12-31 | 70.43% | 0.93% | 0.93% | 38/158 | -1222.98% | 微芯生物 | 95.14% | 行业排名> |
| 2018-12-31 | 69.78% | 18.95% | 18.95% | 36/158 | -208.09% | 多瑞医药 | 95.59% | 行业排名> |
| 2017-12-31 | 58.66% | 2% | 2% | 46/158 | 52.32% | 微芯生物 | 95.81% | 行业排名> |